PDPs save money and are a cost-effective way to save lives and grow economies

The products that PDPs develop provide tremendous value for money and a strong return on investment. PDPs are consistently able to develop products at costs below that of the private sector. For example, DNDi documented the full costs for its research and development of a new chemical entity at €60–190 million, a figure substantially lower than that estimated by private industry. Adaptations of existing drugs can cost €4–32 million. By pooling and leveraging funding from multiple sources, PDPs spread risks across multiple investors and research programs. This means investing in PDPs is a safe and impactful way to save lives, strengthen health systems, and promote economic development, health security, and stability around the world.